Mandip Sachdeva, Ph.D. receives four patents in one year!

Professor, Section Leader, Inventor...

The process of securing a patent is an arduous one, in even the most idyllic circumstances; to receive four in one year after much collaborative, labor-intensive research is phenomenally noteworthy. Such is the case for Mandip Sachdeva, Ph.D., Professor, College of Pharmacy and Pharmaceutical Sciences, Pharmaceutics Section Leader, Editor-in-Chief, Critical Reviews in Therapeutic Drug Carrier Systems. Presently he serves as the Research Core Director for the P20 Center of Excellence Cancer Research Training and Community Services’ activity at FAMU. This center is supported, in part, by a grant from the National Institutes of Health, National Institute on Minority Health Disparities, Grant 1P20MD006738-01. Dr. Sachdeva’s collaborative research projects and outstanding outcomes have yielded four patents since February 2014 to date:

1. Patent #8,647,661 - Surface Modified Multilayered Nanostructures for Dermal Delivery (co-inventor Punit Shah, Ph.D.);

2. Patent #8,715,736 - Nanoparticle Formulations for Skin Delivery (co-inventor Ram Patlolla, Ph.D.);

3. Patent #8,846,616 - Alpha-Melanocyte Stimulating Hormone (a-MSH) as Topical Anti-Inflammatory Agent for the Treatment of Allergic contact Dermatitis and Eczema (co-inventors Cheryl Armstrong, Ph.D. and John Ansel, Ph.D.); and

4. Patent #8,865,206 - Surface Modified Multilayered Nanostructures for Dermal Delivery was also awarded as a Continuation in Part (CIP) application, which is why it has the same name as the first patent.

VP for Research, Timothy E. Moore, Ph.D., stated: “Dr. Sachdeva is a sterling example of how FAMU faculty are using their innovational talents to advance our overall research enterprise.”

Along with the above-referenced patents and discoveries, Dr. Sachdeva, has secured more than $25 million in grant funding from federal agencies and various pharmaceutical companies. He is hopeful that his research will lead to novel and targeted treatment methods for lung cancer and skin inflammatory disorders. Sachdeva received his B.S. degree in pharmacy from Panjab University, India in 1980. He earned his master's and Ph.D. degrees in bio-pharmaceutics from Dalhousie University, Halifax, Nova Scotia, Canada in 1986 and 1989 respectively. He then worked for a pharmaceutical company, SynPhar Laboratories in Edmonton, in Alberta, Canada for four years as a group leader for drug targeting. He may be contacted at Mandip.sachdeva@famu.edu.